Aerocrine's Niox Mino approved by Health Canada

Health Canada's Therapeutic Products Directorate has authorised Aerocrine's Niox Mino for use in identifying allergic airway inflammation. Niox Mino measures fractional exhaled nitric oxide which is a direct, non-invasive way to assess the allergic airway inflammation which characterises many adults and children with asthma. This ten-second breath test can help tell clinicians if patient's asthma is under control by measuring the level of allergic inflammation in their lungs.

This article is tagged to:
Sector: Medical Devices
Geography: Canada

Enter your details to read the full article

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.